FDA Approves Blinatumomab for MRD+ ALL
The FDA has approved blinatumomab for the treatment of patients with minimal residual disease–positive B-cell precursor acute lymphoblastic leukemia.
Advertisement
Read full article (External website)
The FDA has approved blinatumomab for the treatment of patients with minimal residual disease–positive B-cell precursor acute lymphoblastic leukemia.
Read full article (External website)
Leave a Reply
Want to join the discussion?Feel free to contribute!